Augmentation of fibroblast regenerative activity

Patent metadata

Field	Value
Publication number	US-11959102-B2
Application number	US-201816770495-A
Country	US
Kind code	B2
Filing date	Dec 17, 2018
Priority date	Dec 20, 2017
Publication date	Apr 16, 2024
Grant date	Apr 16, 2024

Abstract

Embodiments of the disclosure include methods and compositions for use of prepared fibroblasts and/or conditioned media therefrom. In particular embodiments, the prepared fibroblasts have enhanced regenerative and may have an increase in secretion of one or more cytokines and/or growth factors; may have an increase in anti-apoptotic activity; and/or may have a modulated immunogenicity. In specific embodiments, the fibroblasts are prepared by exposure to hypoxia and/or carbon monoxide.

First claim

What is claimed is:

1. A method of enhancing a therapeutic activity of a plurality of fibroblasts, comprising the step of providing to the fibroblasts an effective amount of a combination of hypoxia and carbon monoxide.

2. The method of claim 1 , wherein the therapeutic activity comprises regenerative activity of the fibroblasts.

3. The method of claim 1 , wherein the fibroblasts have an increase in secretion of one or more cytokines and/or growth factors.

4. The method of claim 1 , wherein the fibroblasts have an increase in anti-apoptotic activity.

5. The method of claim 1 , wherein the immunogenicity of the fibroblasts is modulated.

6. The method of claim 1 , wherein the carbon monoxide is provided to the fibroblasts subsequent to the hypoxia.

7. The method of claim 1 , wherein the carbon monoxide is provided to the fibroblasts at the same time as the hypoxia.

8. The method of claim 1 , wherein an effective amount of the fibroblasts is provided to an individual.

9. The method of claim 8 , wherein the individual has an autoimmune disease, degenerative disease, inflammatory disease, and/or a fibrotic disease.

10. The method of claim 8 , wherein the conditioned medium comprises one or more growth factors and/or one or more cytokines.

11. The method of claim 1 , wherein the hypoxia is 0.1%-10%, 0.1%-5%, 0.1%-2.5%, or 0.1%4% oxygen.

12. The method of claim 1 , wherein the hypoxia occurs for a period of time that is such as at least or no more than between 30 minutes-3 days.

13. The method of claim 1 , wherein the fibroblasts are exposed to one or more growth factors prior to exposure to the hypoxia, carbon monoxide, or a combination thereof.

14. The method of claim 1 , further comprising obtaining a conditioned medium from the fibroblasts.

15. The method of claim 14 , wherein an effective amount of the fibroblasts and/or the conditioned medium is provided to an individual.

16. The method of claim 15 , wherein the individual has an autoimmune disease, degenerative disease, inflammatory disease, and/or a fibrotic disease.

17. The method of claim 15 , wherein the conditioned medium comprises one or more growth factors and/or one or more cytokines.

Assignees

• Figene Llc

Inventors

• O'Heeron Pete
• Ichim Thomas

Classifications

• C12N5/0656 Primary

  Adult fibroblasts · CPC title

• A61K33/00

  Medicinal preparations containing inorganic active ingredients · CPC title

• C12N2500/02

  Atmosphere, e.g. low oxygen conditions · CPC title

• C12N2500/05

  Inorganic components · CPC title

• A61P9/10 Primary

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title